Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Protokinetix Inc (PKTX)

Protokinetix Inc (PKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants Business Wire - Wed Jul 20, 2022

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that the University of Alberta has successfully...

PKTX : 0.0156 (-7.69%)
ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only Business Wire - Fri Jan 14, 2022

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that it will hold its Annual General Meeting...

PKTX : 0.0156 (-7.69%)
ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease Business Wire - Tue Nov 23, 2021

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that it has selected two formulations of its...

PKTX : 0.0156 (-7.69%)
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions Business Wire - Wed May 12, 2021

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV ) to...

PKTX : 0.0156 (-7.69%)
IQV : 223.37 (+0.55%)
ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes Business Wire - Thu Apr 22, 2021

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX) , a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP® (PKX-001) treated...

PKTX : 0.0156 (-7.69%)
ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP® Business Wire - Wed Apr 14, 2021

ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the formulation...

PKTX : 0.0156 (-7.69%)
Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration Business Wire - Wed Apr 7, 2021

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced the publication of a peer reviewed research paper...

PKTX : 0.0156 (-7.69%)
Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision Business Wire - Tue Nov 24, 2020

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced the submission of a research paper describing...

PKTX : 0.0156 (-7.69%)
ProtoKinetix AAGP® Restores Vision in Blind Test Subjects Business Wire - Tue Sep 15, 2020

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of extensive...

PKTX : 0.0156 (-7.69%)
Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada Business Wire - Thu Aug 27, 2020

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that Dr. James Shapiro has received approval...

PKTX : 0.0156 (-7.69%)

Barchart Exclusives

3 High-Yield Dividend Stocks Ready to Soar Barchart - Fri May 3, 6:00PM CDT
These three stocks are cheap, pay a high dividend, and are highly rated. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot